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One of the main challenges in cancer treatment is the administration of active doses of 
chemotherapeutic to a tumor site while minimizing severe side effects. On this basis, 
researchers have developed different materials for achieving both spatial and temporal 
effective release of the active molecule at the therapeutic target.
[1-4]
 Among these materials, 
the locoregional administration of drug-loaded, in situ gelling hydrogels overcomes the 
pharmacokinetic restrictions of intravenous injection and effectively enhances the therapeutic 
ratio.
[5, 6]
 Following this principle, the present work describes the design of a composite 
material which enables a thermally triggered and localized release of a chemotherapeutic 
(doxorubicin), achievable through incorporation of drug-loaded thermosensitive liposomes in 
a thermoresponsive chitosan/β-glycerophosphate (C/β-GP) hydrogel for local treatment. 
Doxorubicin (DOX) is sequentially released from the gel by 1) passive diffusion of entrapped 
free drug and a small portion of drug-loaded liposomes, and 2) external thermal activation of 
the drug-loaded liposomes irreversibly trapped in the gel. The effect of this on-demand 
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scheduled dosing is assayed in vitro with human ovarian carcinoma cells, and is proposed as a 
way to challenge some of the compensatory mechanisms available to tumor cells. By reducing 
the exposure to sublethal doses of chemotherapeutic, the growth of cells with a short doubling 
time is inhibited while also potentially avoiding the development of drug resistance.
[7-9]
 
Our proposed approach combines the in situ gelation of thermoresponsive C/β-GP hydrogels 
and the on-demand release achievable using thermosensitive liposomes, with the aim of 
providing a localized, optimal delivery of chemotherapeutic. C/β-GP-based gelling systems 
have been widely studied because of their biocompatible and biodegradable properties.
[10, 11]
 
However, a feature which makes these hydrogels especially attractive is that they can be 
formulated as a syringable solution at working temperatures that undergoes a gelation at body 
temperature, enabling a minimally invasive delivery and localized cohesion and release of 
encapsulated agents. Studies investigating intratumoral injections of anticancer drug-releasing 
C/β-GP hydrogels in vivo have shown encouraging results.[12]  Lysolipid thermally sensitive 
liposomes (LTSLs) are bilayered spherical vesicles that rapidly change structure upon mild 
hyperthermia (41-43ºC), creating openings in the liposome which release the drug payload.
[13]
 
DOX can be efficiently loaded in LTSLs by the pH gradient method,
[14]
 in which the creation 
of a transmembrane proton gradient induces the accumulation of the drug into the acidic 
interior of the liposome. This mechanism of drug uptake also allows a pH-sensitive release 
when the liposome is subjected to an acid pH, such as in the endosomal compartments after 
cell internalization.
[15] 
The combination of C/β-GP hydrogels with DOX-loaded LTSLs gives rise to a homogeneous 
dispersion (Scheme 1A) that, upon local injection, will become a crosslinked gel entrapping 
the liposomes (Scheme 1C). As a result of its composition, the release of drug from this 
formulation, denoted Lipogel, demonstrates a multistep profile. Initially, a rapid increase in 
DOX release above a therapeutic concentration takes place due to a combination of the 
diffusion of free drug from the gel bolus and a limited release from encapsulated liposomes. 
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Afterwards, to maintain levels of released DOX within an optimal and efficacious 
concentration window, liposomal release can be activated externally through minimally 
invasive application of hyperthermia treatments (Scheme 1E) using radiofrequency, 
microwaves or high-intensity focused ultrasound (HIFU).
[16-18]
 Precisely controlling the drug 
release profile from the hydrogel in this way may enhance efficacy against tumor cells with 
minimal systemic side effects. In addition, the inclusion of hyperthermic stimulation in the 
treatment, may enable chemosensitization in the tumor.
[19, 20] 
DOX-loaded thermosensitive liposomes (hydrodynamic diameter 250 nm) with a transition 
temperature of 41ºC, were prepared. 10% of the DOX within the liposome dispersion was 
unencapsulated (supplementary data) thus enabling an initial burst release from liposome-
entrapping gels. Next, the liposomes were dispersed within a chitosan/β-GP solution and upon 
heating to 37ºC, a stable gel was formed (Figure 1A). Rheological measurements of the 
hydrogels are presented in Figure 1B. As shown, the introduction of the liposomes into the 
gel reduced the temperature of gelation from 35°C to 33°C. However, this is well within an 
acceptable range, whereby gels are liquid and syringable at working temperatures of ~ 25°C.  
Discrete release at different time points up to 7 days is presented in Figure 1C. An early burst 
effect is displayed by Lipogel at a constant 37ºC, as a result of unencapsulated DOX in 
combination with a fraction of DOX released from liposomes under physiological conditions. 
Thereafter, the release rate steadily decreases until the end of the assay. In contrast, the 
amount of DOX released from the materials significantly increases when applying an external 
42ºC pulse for 1 hour at day 2, due to the activation of the thermosensitive liposomes (~ 7-
fold increase in release compared to non-pulsed samples at day 3). This fact indicates that 
both liposomal temperature sensitivity and structural integrity are maintained in the Lipogel 
environment. As a control, it was shown that hydrogels loaded with free DOX (without 
liposomes) did not have an enhanced release at 42ºC, and that free DOX was rapidly released 
4 
 
from the gel at 37ºC (Figure S5), in contrast with the controlled release achievable with 
Lipogel. 
The cumulative release profile from the samples is displayed in Figure 1D. After 2 days, 
when DOX levels have reached a plateau, triggered release provides further dosing for 3 days. 
Additionally, as mentioned above, although the majority of the thermosensitive liposomes is 
irreversibly trapped in the gel, a certain amount of them diffuses through the large pores of the 
C/β-GP matrix. This phenomenon has been observed before,[21] and can be tuned by changes 
in the liposome size. For our selected hydrodynamic diameter, approximately 20% of the 
liposomes are released from Lipogel in a sustained way over 7 days (supplementary data). 
These liposomes are intact, as confirmed by DLS measurements (data not shown), and have 
the capability to release their DOX content upon cellular internalization due to the pH 
changes in the endocytic apparatus of the cell.
[15, 22]
 Ideally, the initial efficacy produced by 
the burst release from Lipogel would initiate apoptosis in a significant portion of gel-exposed 
tumor cells, resembling a tumor priming mechanism.
[23-25]
 Thereafter, a fraction of released 
liposomes could further penetrate into deep areas of the solid tumor. By maximizing the drug 
delivery distance from the gel implant, the release of these liposomes could overcome a major 
limitation on the efficacy of intratumoral treatments.
[9]
  
In order to assess the bioactivity of the Lipogel formulation, human A2780 ovarian carcinoma 
cells were incubated along with gels added to hanging inserts above the cell culture well. In 
this way, DOX and DOX-loaded liposomes released from the sequestered gels diffuse across 
the insert membrane and into the growth media. The growth and viability of cells were 
assessed visually, through Live/Dead
®
 staining (Figure 2A) and quantitatively via a 
PicoGreen
®
 double-stranded (ds)DNA assay (Figure 2B). After 48 hours incubation, a 
significant decrease in dsDNA was observed, demonstrating the efficacy of the first passive 
diffusion of free DOX and drug-loaded liposomes from the gel. Afterwards, the gel-
containing inserts were transferred to another well with intact cells to independently evaluate 
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the activity of DOX released after the external thermal activation of the drug-loaded 
liposomes irreversibly trapped in the gel. Two days after a one hour hyperthermic pulse at 
42ºC, the efficacy of the gels was drastically enhanced when compared to non-pulsed samples. 
In fact, pulsed Lipogel reduced dsDNA to levels comparable to a free DOX control, in which 
cells were incubated continuously with free DOX for four days. The heat pulse itself did not 
produce a significant reduction in cell viability. This result demonstrates that efficacy was 
effectively extended and enhanced through hyperthermia-triggered release and that DOX 
released from Lipogel maintained full bioactivity.         
In summary, here we have reported the design of a novel thermosensitive liposome/hydrogel 
composite that can facilitate an on-demand, localized release of chemotherapeutics. This 
system enables a local control of anticancer drugs scheduling and sequencing, which are key 
parameters in oncological treatments. The possibility to tune the release profiles of different 
therapeutics independently without the compounded side effects associated with combination 
therapies, may lead to more powerful oncologic regimes and synergistic treatment options.
[26, 
27] 
 
 
Experimental Section  
Fabrication of DOX-loaded hyperthermia sensitive liposomes: Thermosensitive liposomes 
were prepared as described by Negussie et al.[28, 29], with slight changes. Briefly, 
dipalmitoyl phosphatidylcholine (DPPC), monostearoyl phosphatidylcholine (MSPC) and 
distearoyl phosphatidylethanolamine-poly(ethylene)glycol 2000 (DSPE-PEG2000) in a molar 
ratio of 85.3: 9.7: 5.0 were dissolved in chloroform and a lipid film was formed in a rotavapor 
under vacuum, at 40°C. The film was kept under N2 gas in order to remove the remaining 
solvent residue. Liposomes were prepared by hydrating the lipid film with 300 mM citrate 
buffer (pH 4.0) at 60°C, aiming for a final lipid concentration of 50 mg/mL. The resulting 
liposomes were extruded through polycarbonate membrane filters at 60°C to achieve a final 
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liposome size of 250 nm and a PDI of 0.18, as measured by DLS using a Malvern CGS-3 
multiangle goniometer (Malvern Ltd., Malvern, U.K., with a JDS Uniphase 22 mW He-Ne 
laser operating at 632 nm, an optical fibre-based detector and a digital LV/LSE-5003 
generator, measurement angle 90º). In order to create a pH gradient for active DOX loading, 
the exterior of liposomes in the resulting suspension was neutralized to pH 7.4 by adding 500 
mM sodium carbonate buffer. Subsequently, liposomes were loaded with DOX by incubation 
at 37°C for 1 hour (DOX: lipid 5:100 w/w, encapsulation efficiency > 90%). The 
unencapsulated DOX molecules were to a large extent removed from the resulting suspension 
by PD10 column purification, while permitting 10% of the DOX within the resulting 
liposome dispersion to remain unencapsulated. 
Preparation of chitosan/β-glycerophosphate gels: Preparation of thermoresponsive C/ β-GP 
gels has been described elsewhere [30]. Briefly, 100 mg of ultra-pure chitosan (UP CL214 
from Pronova Biomedical, Norway) was dissolved in 4.5 mL dH2O at pH 8-9. 350 mg of β-
glycerophosphate was dissolved in 0.5 mL dH2O also at pH 8-9 and added dropwise to the 
chitosan solution. To each 5 g of gel, 208 μL of liposome dispersion was added and gently 
mixed, corresponding to a final DOX concentration of 116 μg/g gel and a final lipid 
concentration of 2.5 mg/g gel. Gels containing free DOX were prepared by dissolving DOX 
in the constituent dH2O, prior to gel preparation, to give a final concentration of 116 μg/g gel 
concentration. 
Rheological testing: The rheological properties of chitosan/β-GP gels were assessed using 
oscillatory measurements on an AR-1000 cone and plate rheometer (TA Instruments). The 
thermoresponsiveness of the gels was assessed as a function of temperature, with storage 
modulus (G′) being used as an indicator of gel structure. The temperature was increased by 
1°C/min using a temperature sweep mode extended between 20 and 50°C at a frequency of 
0.5 Hz. 
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DOX release from liposome-C/β-GP hydrogel composites: 1 g of Lipogel formulation at room 
temperature was transferred into a glass vial and allowed to gel in a water bath for one hour at 
37ºC. Next, 2 mL of Roswell Park Memorial Institute (RPMI-1640) media (Sigma Aldrich, 
Ireland) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin 
(Sigma Aldrich, Ireland) was added and gels were incubated at 37ºC whilst shaking at 100 
rpm. Media were removed at given time points (4 hours, 1, 2, 3, 5 and 7 days) and replaced 
with fresh pre-warmed media. After removing the medium at 2 days, media at 42ºC were 
added to a set of samples, which were incubated at 42ºC for one hour and later incubated at 
37ºC for the rest of the study. All release media samples were ultracentrifuged (45,000 rpm, 
10 min), and the supernatant was analyzed for DOX content via high-performance liquid 
chromatography (HPLC) on an Agilent 1120 Compact LC with a Phenomenex Gemini 5u 
C18 column, mobile phase (95% KH2PO4 20mM pH=3, 5% acetonitrile):acetonitrile 
(75%:25% v/v), UV detection at 480 nm. In order to quantify the intact liposomes released 
from Lipogel, 1 mL of a 0.5% (v/v) Triton X100 solution was added to the pellet remaining 
after aspiration of centrifuged release media, gently mixed and then analyzed by HPLC. All 
samples were analyzed in triplicate and filtered with 0.45 μm Durapore PVDF filters 
(Millipore, Ireland) before measurement. 
Assessment of bioactivity of DOX released from Lipogel: A2780 ovarian carcinoma cells were 
cultured in identical media as that utilized in the DOX release study at 37°C and in a 5% CO2 
environment. To determine the bioactivity of Lipogel-released DOX, cells were seeded into 
24-well plates at a density of 100,000 cells per well with the addition of 500 μL of RPMI-
1640 media. The cells were incubated overnight to allow adherence to occur. 100μL of 
Lipogel was added to transwell cell culture inserts with a pore size of 8μm (Millipore) and 
permitted to thermogelate at 37°C for one hour.  Medium was removed from wells containing 
A2780 cells, inserts containing Lipogel were placed in the wells and media in the wells were 
replaced (1mL basolaterally, 300μL apically). Cells exposed to an equivalent quantity of 
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DOX diluted in 1.3 mL RPMI, or untreated cells acted as positive and negative controls, 
respectively. Samples were analyzed at 48 hours or at this time point underwent a 
hyperthermic pulse (42°C) for one hour before incubation at 37°C for a further 2 days. Inserts 
containing Lipogel were transferred to new wells after 48 hours, to enable completely 
independent examination of the efficacy of the initial and second burst release of DOX from 
the formulation, with and without a hyperthermic pulse. Live/Dead
®
 stain, which stains live 
cells green and dead cells red, was used to assess cytotoxicity visually while a PicoGreen
®
 
dsDNA assay was used to quantitatively assess viable cell numbers (whereby levels of 
dsDNA are utilized as a surrogate measure for the levels of viable cells per well), both 
according to the manufacturer’s instructions. All samples were assayed in triplicate.    
Statistical analysis: 
Two-way ANOVA followed by pairwise Holm-Sidak analysis was performed. Error is 
reported as standard deviation (SD) and significance was determined using a probability value 
of P < 0.05. A minimum of N=3 replicates were performed for all experiments. 
 
Supporting Information  
Supporting Information is available from the Wiley Online Library or from the author. 
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Scheme 1. A) Lipogel is fully syringable and is conceived as a local injectable, consisting of a 
chitosan/β-GP thermoresponsive gel hosting a suspension of DOX-loaded thermosensitive 
liposomes. B) Release from the gel in situ is controllable using minimally invasive 
hyperthermia, achievable using a modality such as high intensity focused ultrasounds. A small 
portion of drug-loaded liposomes is released from Lipogel maximizing the drug delivery 
distance from the gel implant. C) The majority of liposomes are locked into the gel upon 
initiation of crosslinking during thermogelation. D, E) Liposomes sequester the majority of 
drug at body temperature, but rapidly become more permeable upon mild hyperthermia and 
release their drug payload.  
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Figure 1. A) Photographs of Lipogel before (20ºC) and after (37ºC) gelation. B) Storage 
modulus of a regular chitosan/glycerophosphate (C/β-GP) gel and a DOX-loaded 
liposome/hydrogel composite (Lipogel) as a function of temperature. Gels containing 
liposomes began to thermorespond at 33°C while unaltered gels thermoresponded at 35°C. C) 
and D) Non-cumulative and cumulative DOX release profiles from Lipogel with and without 
a one hour pulse at 42ºC, indicated by the arrow. Given that  ̴ 20% of the drug-loaded 
liposomes are released from the gel over 7 days (supporting information), a significant 
fraction (around 40%) of DOX remains trapped in the pulsed Lipogel after 7 days, probably 
due to electrostatic interactions [31].  
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Figure 2. A) Fluorescent micrographs of A2780 ovarian carcinoma cells which were 
live/dead stained after exposure to Lipogels with and without the hyperthermic pulse. Free 
DOX was employed as positive control. B) dsDNA levels of the same samples, as assessed by 
PicoGreen assay. A significant reduction in cell number is apparent in samples treated with 
free DOX and Lipogel at day 2 or day 4 after a pulse. 
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A novel drug delivery system, enabling an in situ, thermally triggered drug release is 
described, consisting of an injectable thermoresponsive chitosan hydrogel containing 
doxorubicin-loaded thermosensitive liposomes. The design, fabrication, characterization and 
an assessment of in vitro bioactivity of this formulation is detailed. Combining on-demand 
drug delivery with in situ gelation has resulted in a promising candidate for local 
chemotherapy.  
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Figure S1. Differential scanning calorimetry (TA Instruments DSC Q2000 apparatus) 
thermogram of doxorubicin-loaded liposomes showing phase transition temperature at 41ºC.  
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Figure S2. Hydrodynamic size distribution of extruded liposomes by dynamic light scattering 
(DLS).  
 
 
Figure S3. An analysis of DOX release from thermosensitive liposomes in PBS. Liposome 
dispersion was held at 37º C or 42º C for up to 60 minutes. Up to 65% of encapsulated DOX 
was released within 60 minutes.     
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Figure S4. Rheological characterization of different hydrogel compositions as a function of 
time, keeping temperature constant at 37°C. Unmodified gels or gels containing free DOX or 
liposomal DOX (same DOX concentration) all demonstrated thermoresponsive behaviour. 
Both free DOX and liposomal DOX produced a reduction in the maximum storage modulus 
achieved. However, all gels resisted dissolution when incubated in aqueous media and 
resisted disruption upon handling. 
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Figure S5. Cumulative DOX release from chitosan/β-GP gels containing free DOX 
maintained at 37ºC or 42ºC, or gels containing liposomal DOX (same DOX concentration) 
maintained at 42ºC. Release at 42ºC from free DOX and liposomal DOX gels was almost 
identical, suggesting that liposomes were able to release all encapsulated DOX at this 
temperature. Interestingly, free DOX gels maintained at 37ºC demonstrated a more rapid 
release of DOX, which is attributable to a lesser degree of polymer network organization at 
this lower temperature, and the resultant effect on drug diffusion [1]. Changes in gel strength 
as a function of temperature are represented by the variation of the storage modulus in Figure 
1B in the main text. 
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Figure S6. Sustained release of intact DOX liposomes from a chitosan/β-GP gel at 37ºC over 
seven days. In order to quantify the liposomes released from Lipogel, a 0.5% (v/v) Triton 
X100 solution was added to the pellet remaining after aspiration of centrifuged media 
obtained in the release studies, gently mixed and then analyzed by HPLC. Release is 
expressed as a percentage of the total amount of liposomes (total DOX concentration) initially 
encapsulated within the gel. 
 
Figure S7. An analysis of DOX release from thermosensitive liposomes at pH 5, as an 
approximation of release upon endosomal integration. Liposome dispersion was held at 37ºC 
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in 120 mM ammonium acetate buffer for the duration of the experiment. DOX uptake induced 
by pH gradients implies its accumulation in the acidic interior of the liposome until 
[∆H+]in/[∆H
+
]out = [H
+
]in/[H
+
]out.
[22]
 Therefore, liposomes produced a rapid release of DOX in 
response to reduced pH, meaning that tumor cells which internalize released liposomes could 
be exposed to encapsulated DOX upon endocytosis. 
 
Figure S8. A comparison of non-cumulative and cumulative DOX release profiles from 
Lipogel in supplemented cell culture medium and PBS with a one hour pulse at 42ºC, 
indicated by the arrow. Almost identical profiles are found, suggesting that serum proteins do 
not affect DOX release from the gels. 
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